Neurogene (NASDAQ:NGNE) today reported financial results for the fourth quarter and full year ended December 31, 2025, delivering a "beat" against Wall Street’s bottom-line expectations.
The New York-based biotechnology company, which specializes in genetic medicines for complex neurological conditions, reported a fourth-quarter net loss of $24.7 million.
On a per-share basis, the loss narrowed to $1.12, outperforming the market consensus.
According to Zacks Investment Research, the average estimate among six analysts had projected a loss of $1.20 per share.
This narrower loss reflects disciplined operational scaling as the company transitions its lead programs further into clinical development.
For the full year 2025, Neurogene reported a total net loss of $90.4 million, or $4.24 per share, a reflection of the intensive R&D investment required for its proprietary EXACT gene regulation technology.
The 2025 fiscal year was marked by significant clinical progress, particularly for NGN-401, the company’s investigational gene therapy for Rett syndrome.
By utilizing its EXACT platform, Neurogene aims to deliver therapeutic levels of the MECP2 gene while avoiding the toxicities typically associated with over-expression.
This technological differentiation remains a key focus for investors, as the company works toward providing a potential best-in-class treatment for a patient population with high unmet needs.